Evidence map›Paper›PMID 39276177›Full record

ArticleJournal of neuro-oncology2024

Comparisons of clinical characteristics, treatments, and outcomes among different pathological subtypes of chondrosarcoma in the spine.

Jian Sun, Zhipeng Wu, Jian Jiao, Haifeng Wei, Xinghai Yang, Tielong Liu, Jian Zhao, Cheng Yang, Wei Xu, Zhenhua Zhou and 2 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Chondrosarcoma of the mobile spine: impact of tumor status at referral and surgical strategy on oncological outcome.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jian Sun *Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Zhipeng Wu *Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Jian Jiao *Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Haifeng WeiDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Xinghai YangDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Tielong LiuDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Jian ZhaoDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Cheng YangDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Wei XuDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Zhenhua ZhouDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China. article_zzh@126.com.
Ting WangDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China. wangt_boneleven@163.com.
Jianru XiaoDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Naval Medical University, #415 Fengyang Road, Shanghai, 200003, China. jianruxiao83@163.com.

Funding

National Natural Science Foundation of China 81874180National Natural Science Foundation of China 81972505National Natural Science Foundation of China 82173028
6 · The paper itself

Abstract

introductionSpinal chondrosarcoma exhibits higher invasiveness and a worse prognosis compared to chondrosarcoma in the extremities. The prognosis and therapeutic plan vary greatly among different pathological subtypes of chondrosarcoma. This study aimed to analyze the differences in clinical characteristics, molecular features, therapeutic effects, and prognostic factors among the subtypes of chondrosarcoma in the spine.

methodsA retrospective review was conducted on 205 patients with spinal chondrosarcoma. The clinical features and immunohistochemical (IHC) markers were compared among the pathological subtypes of chondrosarcoma grade 1, grade 2, grade 3, mesenchymal chondrosarcoma (MCS), dedifferentiated chondrosarcoma (DCS), and clear cell chondrosarcoma (CCCS). Chondrosarcoma grade 1/2/3 are collectively referred to as conventional chondrosarcoma (CCS) for multivariate survival analysis. Univariate and multivariate analyses were performed to investigate independent prognostic factors for overall survival (OS) and recurrence-free survival (RFS) in patients with spinal chondrosarcoma. Furthermore, independent prognostic factors for OS and RFS were identified in CCS and MCS.

resultsMCS patients were younger than the other subtypes. Patients with chondrosarcoma grade 1/2 had better OS than those with chondrosarcoma grade 3, MCS and DCS, while only chondrosarcoma grade 1 patients showed better RFS than chondrosarcoma grade 2/3, MCS and DCS patients. Ki-67 index was higher in chondrosarcoma grade 3, MCS and DCS than chondrosarcoma grade 1/2. The comparison of IHC markers further highlighted the overexpression of P53/MDM2 in MCS and DCS. Gross total resection, including en-bloc and piecemeal resection, significantly improved OS and RFS for CCS patients, while only en-bloc resection significantly improved the prognosis of MCS patients. Chemotherapy appeared to be important for the OS of MCS patients.

conclusionP53/MDM2 pathway was upregulated in MCS and DCS compared to chondrosarcoma grade 1/2. Radical tumor resection is crucial for the treatment of spinal chondrosarcoma, while MCS patients require further comprehensive treatments perioperatively.

Indexed as

ChondrosarcomaSpinal NeoplasmsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm GradingPrognosisRetrospective StudiesTreatment OutcomeTumor Suppressor Protein p53Biomarkers, TumorTumor Suppressor Protein p53Clinical characteristicsIHC markersPathological subtypesPrognostic factorsSpinal chondrosarcoma

Identifiers

PMID39276177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.